Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds

Journal of Medicinal Chemistry

Volumn 58, Issue 17, 2015, Pages 6899-6908

  Wu, Fangrui ^a   Jiang, Hong ^a   Zheng, Baisong ^a   Kogiso, Mari ^a   Yao, Yuan ^a   Zhou, Chao ^a   Li, Xiao Nan ^a   Song, Yongcheng ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEMETHYLASE; ISOCITRATE DEHYDROGENASE 1; THIOHYDANTOIN DERIVATIVE; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; HISTONE; ISOCITRATE DEHYDROGENASE; PROTEIN BINDING;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CRYSTAL STRUCTURE; DRUG SYNTHESIS; ENZYME KINETICS; EPIGENETICS; GENE MUTATION; GLIOMA; GLIOMA CELL; HISTONE METHYLATION; HUMAN; HUMAN CELL; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; KINETICS; METABOLISM; METHYLATION; MUTATION; PATHOLOGY; PROTEIN CONFORMATION; SYNTHESIS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTARATES; HISTONES; HUMANS; ISOCITRATE DEHYDROGENASE; KINETICS; METHYLATION; MODELS, MOLECULAR; MUTATION; NEOPLASTIC STEM CELLS; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; THIOHYDANTOINS;

EID: 84941578432     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00684     Document Type: Article

References (30)

1. Xu, X.; Zhao, J.; Xu, Z.; Peng, B.; Huang, Q.; Arnold, E.; Ding, J. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity J. Biol. Chem. 2004, 279, 33946-33957 10.1074/jbc.M404298200
2. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A., Jr.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme Science 2008, 321, 1807-1812 10.1126/science.1164382
3. Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Wang, P.; Kim, S. H.; Ito, S.; Yang, C.; Xiao, M. T.; Liu, L. X.; Jiang, W. Q.; Liu, J.; Zhang, J. Y.; Wang, B.; Frye, S.; Zhang, Y.; Xu, Y. H.; Lei, Q. Y.; Guan, K. L.; Zhao, S. M.; Xiong, Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases Cancer Cell 2011, 19, 17-30 10.1016/j.ccr.2010.12.014
4. Gross, S.; Cairns, R. A.; Minden, M. D.; Driggers, E. M.; Bittinger, M. A.; Jang, H. G.; Sasaki, M.; Jin, S.; Schenkein, D. P.; Su, S. M.; Dang, L.; Fantin, V. R.; Mak, T. W. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations J. Exp. Med. 2010, 207, 339-344 10.1084/jem.20092506
5. Yan, H.; Parsons, D. W.; Jin, G.; McLendon, R.; Rasheed, B. A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G. J.; Friedman, H.; Friedman, A.; Reardon, D.; Herndon, J.; Kinzler, K. W.; Velculescu, V. E.; Vogelstein, B.; Bigner, D. D. IDH1 and IDH2 mutations in gliomas N. Engl. J. Med. 2009, 360, 765-773 10.1056/NEJMoa0808710
6. Hartmann, C.; Meyer, J.; Balss, J.; Capper, D.; Mueller, W.; Christians, A.; Felsberg, J.; Wolter, M.; Mawrin, C.; Wick, W.; Weller, M.; Herold-Mende, C.; Unterberg, A.; Jeuken, J. W.; Wesseling, P.; Reifenberger, G.; von Deimling, A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Acta Neuropathol. 2009, 118, 469-474 10.1007/s00401-009-0561-9
7. Amary, M. F.; Bacsi, K.; Maggiani, F.; Damato, S.; Halai, D.; Berisha, F.; Pollock, R.; ODonnell, P.; Grigoriadis, A.; Diss, T.; Eskandarpour, M.; Presneau, N.; Hogendoorn, P. C.; Futreal, A.; Tirabosco, R.; Flanagan, A. M. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours J. Pathol. 2011, 224, 334-343 10.1002/path.2913
8. Dang, L.; White, D. W.; Gross, S.; Bennett, B. D.; Bittinger, M. A.; Driggers, E. M.; Fantin, V. R.; Jang, H. G.; Jin, S.; Keenan, M. C.; Marks, K. M.; Prins, R. M.; Ward, P. S.; Yen, K. E.; Liau, L. M.; Rabinowitz, J. D.; Cantley, L. C.; Thompson, C. B.; van der Heiden, M. G.; Su, S. M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 2009, 462, 739-744 10.1038/nature08617
9. Ward, P. S.; Patel, J.; Wise, D. R.; Abdel-Wahab, O.; Bennett, B. D.; Coller, H. A.; Cross, J. R.; Fantin, V. R.; Hedvat, C. V.; Perl, A. E.; Rabinowitz, J. D.; Carroll, M.; Su, S. M.; Sharp, K. A.; Levine, R. L.; Thompson, C. B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate Cancer Cell 2010, 17, 225-234 10.1016/j.ccr.2010.01.020
10. Lu, C.; Ward, P. S.; Kapoor, G. S.; Rohle, D.; Turcan, S.; Abdel-Wahab, O.; Edwards, C. R.; Khanin, R.; Figueroa, M. E.; Melnick, A.; Wellen, K. E.; ORourke, D. M.; Berger, S. L.; Chan, T. A.; Levine, R. L.; Mellinghoff, I. K.; Thompson, C. B. IDH mutation impairs histone demethylation and results in a block to cell differentiation Nature 2012, 483, 474-478 10.1038/nature10860
11. Turcan, S.; Rohle, D.; Goenka, A.; Walsh, L. A.; Fang, F.; Yilmaz, E.; Campos, C.; Fabius, A. W.; Lu, C.; Ward, P. S.; Thompson, C. B.; Kaufman, A.; Guryanova, O.; Levine, R.; Heguy, A.; Viale, A.; Morris, L. G.; Huse, J. T.; Mellinghoff, I. K.; Chan, T. A. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 2012, 483, 479-483 10.1038/nature10866
12. Prensner, J. R.; Chinnaiyan, A. M. Metabolism unhinged: IDH mutations in cancer Nat. Med. 2011, 17, 291-293 10.1038/nm0311-291
13. Garber, K. Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia J. Natl. Cancer Inst. 2010, 102, 926-928 10.1093/jnci/djq262
14. Popovici-Muller, J.; Saunders, J. O.; Salituro, F. G.; Travins, J. M.; Yan, S.; Zhao, F.; Gross, S.; Dang, L.; Yen, K. E.; Yang, H.; Straley, K. S.; Jin, S.; Kunii, K.; Fantin, V. R.; Zhang, S.; Pan, Q.; Shi, D.; Biller, S. A.; Su, S. M. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo ACS Med. Chem. Lett. 2012, 3, 850-855 10.1021/ml300225h
15. Rohle, D.; Popovici-Muller, J.; Palaskas, N.; Turcan, S.; Grommes, C.; Campos, C.; Tsoi, J.; Clark, O.; Oldrini, B.; Komisopoulou, E.; Kunii, K.; Pedraza, A.; Schalm, S.; Silverman, L.; Miller, A.; Wang, F.; Yang, H.; Chen, Y.; Kernytsky, A.; Rosenblum, M. K.; Liu, W.; Biller, S. A.; Su, S. M.; Brennan, C. W.; Chan, T. A.; Graeber, T. G.; Yen, K. E.; Mellinghoff, I. K. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells Science 2013, 340, 626-630 10.1126/science.1236062
16. Zheng, B.; Yao, Y.; Liu, Z.; Deng, L.; Anglin, J. L.; Jiang, H.; Prasad, B. V.; Song, Y. Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase ACS Med. Chem. Lett. 2013, 4, 542-546 10.1021/ml400036z
17. Liu, Z.; Yao, Y.; Kogiso, M.; Zheng, B.; Deng, L.; Qiu, J. J.; Dong, S.; Lv, H.; Gallo, J. M.; Li, X.-N.; Song, Y. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, SAR and Selective Antitumor Activity J. Med. Chem. 2014, 57, 8307-8318 10.1021/jm500660f
18. Deng, G.; Shen, J.; Yin, M.; McManus, J.; Mathieu, M.; Gee, P.; He, T.; Shi, C.; Bedel, O.; McLean, L. R.; Le-Strat, F.; Zhang, Y.; Marquette, J. P.; Gao, Q.; Zhang, B.; Rak, A.; Hoffmann, D.; Rooney, E.; Vassort, A.; Englaro, W.; Li, Y.; Patel, V.; Adrian, F.; Gross, S.; Wiederschain, D.; Cheng, H.; Licht, S. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule J. Biol. Chem. 2015, 290, 762-774 10.1074/jbc.M114.608497
19. Yang, B.; Zhong, C.; Peng, Y.; Lai, Z.; Ding, J. Molecular mechanisms of off-on switch of activities of human IDH1 by tumor-associated mutation R132H Cell Res. 2010, 20, 1188-1200 10.1038/cr.2010.145
20. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M. A.; Dick, J. E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 1994, 367, 645-648 10.1038/367645a0
21. Luchman, H. A.; Stechishin, O. D.; Dang, N. H.; Blough, M. D.; Chesnelong, C.; Kelly, J. J.; Nguyen, S. A.; Chan, J. A.; Weljie, A. M.; Cairncross, J. G.; Weiss, S. An in vivo patient-derived model of endogenous IDH1-mutant glioma Neuro. Oncol. 2012, 14, 184-191 10.1093/neuonc/nor207
22. Wan, F.; Zhang, S.; Xie, R.; Gao, B.; Campos, B.; Herold-Mende, C.; Lei, T. The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research Brain Pathol. 2010, 20, 877-889 10.1111/j.1750-3639.2010.00379.x
23. Laks, D. R.; Masterman-Smith, M.; Visnyei, K.; Angenieux, B.; Orozco, N. M.; Foran, I.; Yong, W. H.; Vinters, H. V.; Liau, L. M.; Lazareff, J. A.; Mischel, P. S.; Cloughesy, T. F.; Horvath, S.; Kornblum, H. I. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma Stem Cells 2009, 27, 980-987 10.1002/stem.15
24. Chaichana, K.; Zamora-Berridi, G.; Camara-Quintana, J.; Quinones-Hinojosa, A. Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies Stem Cells 2006, 24, 2851-2857 10.1634/stemcells.2006-0399
25. Liu, Z.; Zhao, X.; Mao, H.; Baxter, P. A.; Huang, Y.; Yu, L.; Wadhwa, L.; Su, J. M.; Adesina, A.; Perlaky, L.; Hurwitz, M.; Idamakanti, N.; Police, S. R.; Hallenbeck, P. L.; Hurwitz, R. L.; Lau, C. C.; Chintagumpala, M.; Blaney, S. M.; Li, X. N. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma Neuro. Oncol. 2013, 15, 1173-1185 10.1093/neuonc/not065
26. Otwinowski, Z.; Minor, W. In Macromolecular Crystallography, Part A, Method Enzymology; Carter, C. W., Jr.; Sweet, R. M., Eds.; Academic Press: New York, 1997; Vol. 276, pp 307-326.
27. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674 10.1107/S0021889807021206
28. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255 10.1107/S0907444996012255
29. Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 213-221 10.1107/S0907444909052925
30. Tomašić, T.; Mašič, L. P. Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation Expert Opin. Drug Discovery 2012, 7, 549-560 10.1517/17460441.2012.688743